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ABSTRACT
DEVELOPMENT OF PHARMACOPHORE AND CoMFA STUDIES
FOR a2 RECEPTOR LIGANDS
by
Laura Ann Wirpsza

This study describes the development of a pharmacophore and CoMFA model for sigma
2 (a2) receptor ligands. CoMFA studies were performed for 32 bioactive a2 receptor
ligands using the radioligand [H 3 ] (+) DTG in the presence of pentazocine. The
pharmacophore was derived using Distance Comparisons (DISCOtech) from eight
partially to highly active (52 receptor ligands. All 32 compounds were calculated in three
methods: AM1, HF/3-21G*, and B3LYP/3-21G* methods. These methods run in
Gaussian 98 determined the geometry optimization and electrostatic charges for each
molecule. CoMFA maps were developed using SYBYL ver. 7.2 to compare the
electrostatic and steric properties of each calculation and molecule. With "leave-oneout" cross validation, the numbers of optimal components was determined. No cross
validation was performed in a training set using the optimal components for each
analysis. After the completion of a test set, it was verified that CoMFA models derived
from HF/3-21G* optimized geometries and atomic charges are more reliable in
predicting the bioactivities of a2 receptor ligands. Using the HF/3-21G* analysis, new
active a2 receptor ligands were designed and pKi values were predicted. It was
determined that active a2 receptor ligands require localization on the benzene ring
contributed through an electron withdrawing group.
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CHAPTER 1
OUTLINE

Molecular Modeling has been an essential tool for the development of drug design using
various methods. Two of these methods: pharmacophore derivation and CoMFA
(Comparative Molecular Field Analysis), determine the molecular structure and function
for biological receptors. There has been a significant amount of study on ai receptor
ligands, and the al receptor has been isolated and cloned. However, the second subtype,
a2 receptor, has fewer active ligands and only one is commercially available. This
research was conducted to determine a pharmacophore model for a2 receptor ligands and
to perform a CoMFA study using various partially to highly active a2 compounds.
The objectives of the research are:
1) To derive a pharmacophore model for a2 receptor ligands, using highly active
compounds from different classes.

2) To perform an alignment of 32 compounds to perform a validated CoMFA
study for a2 receptor ligands.

3) To compare semi-empirical, density functional, and ab initio calculations to
the CoMFA studies on a2 ligands.
4) To design new a2 ligands from CoMFA results.
Chapter 1 presents an outline and objectives of this research.
Chapter 2 contains QSAR methodology. Section 2.1 describes biological activity.
Section 2.2 gives approaches to developing a QSAR methodology with sections focusing
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on Alignment, Partial Least Squares, and Electrostatic and Steric Properties.
Chapter 3 contains CoMFA studies using semi-empirical, density functional, ab
initio calculation methods and a pharmacophore derivation using DISCOtech on a2
receptor ligands. Section 3.1 shows a selection of a2 ligands, choice of conformation, a
pharmacophore derivation using DISCOtech, geometry optimization and atomic charges
calculations, alignments of optimized structures, and CoMFA models. Section 3.2
contains a discussion of pharmacophore results, comparative molecular field analyses,
validation of CoMFA models, and design of new ligands. Section 3.3 presents a summary
of a2 receptor ligands.
Chapter 4 presents a general conclusion from this study. Suggestions for future
work can be found in Section 4.1.

CHAPTER 2
BACKGROUND
2.1 Bioactivity of Receptor Ligands
Inhibition of enzymes is found through interactions with their respective ligands. The
type of inhibition is determined by the substrate interaction with the enzyme. Equation 1
presents the rate between an enzyme (E) and inhibitor (I) forming an enzyme inhibitor
(EI) complex. This three species model, (E, I, EI) represent the case with a2 receptors and
ligand interactions.

Competitive inhibition is the focus in this study using the true equilibrium constant (Ki=
[E][I]/[EI]), termed the inhibition constant [1, 2]. The pKi (pKi =-log [Ki]) used was
collected from various in vitro and in vivo studies with a range of activity and selectivity.

2.2 QSAR Methodology
To determine the molecular shape in a biological system, QSAR methods are used. First,
a structure is energy minimized using a program such as AM1 and the electron
distribution in the compound is calculated. The program, SYBYL, places the molecules
in a box of points, producing a lattice to represent hypothetical receptor space and
surface. In the data matrix, steric, electrostatic, and hydrophobic interaction energies are
calculated [2]. These calculations are validated using Partial Least Squares and cross

3

4
validation methods to determine the accuracy of prediction for biological activity viewed
through a CoMFA contour map [3, 4].

2.2.1 Alignment
Two questions need to be asked during a CoMFA study: 1) what is the conformation of
the molecule when bound to its biological target? 2) How can a CoMFA map describe the
electrostatic charges and steric properties of the molecules? The first step in the CoMFA
is to energy-minimize the molecule using different techniques going from simpler
approximations (molecular mechanics) to more sophisticated methods (semi empirical
calculations, ab initio optimizations). Since they do not have many conformations, rigid
compounds act as a template when overlapping non rigid molecules. Flexible molecules
have local energy minimum conformations. For establishing a realistic representation,
molecules used in the CoMFA study have the following requirements; one or more
rotatable bonds, belonging to different chemical series that bind to the macromolecular
target. To find similarities between ligands a consistent alignment is essential.
Differences in field values at each lattice point should reflect differences in structure only,
not chance variations in model geometry [3, 4].
The main techniques commonly used are classical fit of selected atom pairs, or
fitting steric and (or) electrostatic fields by minimizing the differences at each lattice
point between a candidate and a template molecule. The Field Fit method has been found
to compute better cross-validated correlations than alignments based on crystal evidence.
This function minimizes the entropy contribution of free energy of binding by forcing the
aligned molecules to share a common global shape and location in the 3D lattice [3, 4].
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Some problems with alignment include the use of different structural classes of ligands
that bind to the receptor [3].

2.2.2 Partial Least Squares
A QSAR study cannot be successful if the structural limits do not relate to the differences
in biological activity. For each compound in the CoMFA study, a structural column
records the intensity of a particular type of interaction, at a distinct point in space, with a
probe atom of specified charge and steric properties. The electrostatic effects are
calculated and values are recorded into a table [4].
The resulting linear equation presents a relation between the biological activities
and the intensity of the exerted fields. Partial Least Squares (PLS) generates a better set
of coefficients (extract a new component), criterion maximized to the degree of
commonality between all structural limit columns and experimental data. During the
evaluation phase of a PLS iteration, the criterion for acceptance of the principal
component generated is based on the improvement of prediction of the biological data.
PLS is assessed through cross validation, where one or more of the active ligands are
omitted. The resulting equation is used to predict the biological activity value for the
omitted compounds. PLS is used to calculate PRESS (Predictive Residual Sum of
Squares) expressed as q 2 or r2 values. Values of q 2 can range from 1.0 to less than zero. A
value of 1.0 indicates a perfect prediction while negative values of q 2 arise from
accumulated prediction error which is greater than 'no model at all.' The q 2 value and its
associated residual graph represents the merit and robustness of a QSAR for predicting
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the activity of the molecules. The r2 is a measurement of how well a particular model
reproduces or fits the input data. In this case, PRESS is replaced by the sum of squares of
the differences between the least-squares fit and the experimental observations [4].
One disadvantage of PLS is that the magnitude of one variable relative to another
can strongly affect the resulting factors, so that the question of 'scaling' is an important
one [4].

2.2.3 Distribution of Steric and Electrostatic Properties
Understanding natural molecules through the influence of their binding, leads to the
design of new molecules that have similar pharmacological effects. Any potential drug
molecule must be engineered to bind tightly to the desired target receptor with assets such
as; non-toxicity, chemical stability, and bioavailability. As a result of studying the
electrostatic charges and steric properties, a cohesive interaction between ligand and
receptor can be found [1, 5].
The contribution of electrostatics to binding is non-intuitive. Placing a polar or
charged chemical group in the prospective drug molecule may create favorable
interactions with the target molecule and solvent. This trade-off between favorable
interaction and unfavorable desolvation free energies is the concern of charge
optimization. Optimizing the ligand charge distribution ensures that electrostatics
contributes favorably to the binding process. Optimization can affect computed binding
affinities through different levels of calculations and alignment of functional groups[4].
Potentially repulsive interaction energy also known as steric energy is another
essential portion of receptor ligand interaction. Studying the intramolecular and
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intermolecular interactions of a molecule one can understand the steric contributions of
ligands [2].

CHAPTER 3
DEVELOPMENT OF PHARMACOPHORE AND CoMFA STUDY FOR SIGMA 2
RECEPTOR LIGANDS
3.1 Introduction
Since the 1970s a receptors have been the focus of physiological studies [6]. Originally,
these compounds were mistaken for opioid and phencyclidine (PCP) receptors [6-10].
Once classified and initially studied, a receptors were separated into three subgroups: at,
a2, and a3 . al Receptors have been cloned with the molecular weight of —25 kDa.
Presently the a2 receptor has a molecular weight of 18-21.5 kDa [7, 12] and has not been
cloned. The a3 receptor has been shown to modulate tyrosine hydroxylase (TH) and
dopamine synthesis in striatum, represented by a separate class of ligands [12]. These
receptors have a widespread distribution in the central nervous system (CNS) and are
found in a range of organs and tissues [7].
al Receptors are associated with CNS disorders such as depression,
schizophrenia, and dementia. Agonists are valued as neuroprotective agents, while
antagonists may help alleviate cocaine addiction [8]. The pharmacophore for al has been
derived and many active ligands have been synthesized through various sources [13].
Manallack used various classes of molecules to determine the first al pharmacophore [6].
This model was further developed by Gund and Shukia in 1991 using electrostatic and
steric calculations [14]. Glennon and coworkers [15,16] made further revisions by
presenting a general structural feature with two hydrophobic regions and an amine site
(distance from the primary hydrophobic region to the amine is 6-10
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A, distance from the
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secondary hydrophobic region to the amine center is 2.5-3.9 A). Gund and coworkers
[17] developed a al pharmacophore using more recent ligands. They determined four
necessary regions and a nitrogen atom: R1 (0.85, 7.26, 0.30); R2 (5.47, 2.40, -1.51) R3
(-2.57, 4.82, -7.10); N (-0.71,3.29,-6.40); carbon centroid (3.16,4.83, -0.60), where R1,
R2 were constructed onto the aromatic ring of each compound to present hydrophobic
interactions with the receptor; and R3 represented a hydrogen bond between the nitrogen
atom and the receptor. These models present two hydrophobic centers with nitrogen
donating lone pair electrons to the al receptor. A few examples of highly active σ1
compounds include: PD144418, Spipethiane, Haloperidol, (+)-Pentazocine, and PRE084
(Table 3.1) [13-17].
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Table 3.1 Binding and Functional Data of Known Active σ1 Receptor Ligan

Haloperidol

(+) Penatzocine

PRE084

PD144418

Spipethiane
Compounds
Haloperidol
(+)Pentazocine
PRE084
PD144418
Spipethiane
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New research has presented several active a2 receptor ligands as well as
suggesting a potential role of the a2 receptor in regulation of cellular proliferation and
apoptosis [2, 6]. The regulation of cell proliferation consists of intracellular membrane
bound a2 receptors, localized on organelles known to store calcium. These receptors also
can cause the release of calcium, used in cell signaling and (or) for the induction of
apoptosis. a2 Agonists may also be useful as anti-neoplastic agents [11]. Compounds with
moderate a2 activity include phenyl morphan CD-184 28 [7, 10] (Table 3.2),
trishomocubane derivatives 29 [18] (Table 3.2), BIMU-1 5 [7, 19] (Table 3.1). 1,3-di (2toly1) guanidine (DTG) 27 is the standard for nonspecific binding of a receptors (Table
3.2) [2-12]. Recently, there has been a pharmacophore developed for the a2 receptor
using GRIND (GRid INdependent Descriptors), a program that does not use alignment,
for a series of α-tropanyl ligands. The model was able to prove two hydrophobic areas
and an H-bond donor receptor region with non-covalent bonds present. PLS models for
the a2 affinity had r2=0.83, q 2 =0.63 [20]. There has been little further development for a
pharmacophore of a2.
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Table 3.2 Binding and Functional Data of Rigid c52 Receptor Ligands

BIMU-1 (5)

CB-184 (28)

1,3-di (2-tolyl) guanidine (DTG) (27)

Compounds
28*
5*t
27
29*

Configuration
(+)-1R,5R
-

ANSTO-19 (Trishomocubane Derivative) (29)

al Ki(nM)
7436+308
6300
152+1

02 Ki (nM)

σ1/σ2

13.4+2.0
32f 15.2
28.2f 1.4
20±4

554.93 [7]
- [19]
- [10]
7.60 [18]

* Indicates included in Pharmacophore Derivation. t Indicates included in CoMFA test set.

Pharmacophore identification methods apply to a series of molecules which are
known to bind to a receptor, even when the three dimensional structure of the receptor is
unknown. Common features from the active compounds are aligned to determine possible
conformations and the minimum requirement for binding. Superimposing moderately to
highly active compounds with rigid compounds helps to better define the geometry of the
pharmacophore for the ligands, since in flexible ligands there are numerous
conformational possibilities [20]. Comparative Molecular Field Analysis (CoMFA) is
able to calculate bioactivity properties of various 02 ligands obtained from different
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functional groups of the compounds. Using the training sets of five different molecules,
the models are verified based on q 2 and r 2 values using the alignment from the
pharmacophore model [14].
Current development in 02 receptor ligands have presented three series of
compounds that are moderate to highly bioactive: 1-aralkyl-4-benzylpiperidine [9], 1aralkyl-4-benzylpiperazine [9], 1-cyclohexylpiperazines [10] and N-substituted 9azabicylo [3.3.1] nonan-3α-yl carbamate [7] analogues. These new compounds are
flexible and have many conformations (Tables 3.3-3.6). Recently, PB28 2, a member of
the 1-cyclohexylpiperazine class (Table 3.5), has been synthesized and represents one of
the first highly potent a2 receptor ligand agonists [21]. Location of different substituents
groups and hydrophobic groups affect the binding to the a2 receptor.
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Table 3.3 Binding and Functional Data of 1-aralkyl-4-benzylpiperidine Derivatives [9]

* Indicates included in Pharmacophore Derivation.

f Indicates included in CoMFA test set.
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Table 3.4 Binding and Functional Data of 1-aralkyl-4-benzylpiperazine Derivatives [9]

* Indicates included in Pharmacophore Derivation. t Indicates included in CoMFA test set.
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Table 3.5 Binding and Functional Data of 1-cyclohexylpiperazine Derivatives [10]

* Indicates included in Pharmacophore Derivation. t Indicates included in CoMFA test set.
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Table 3.6 Binding and Functional Data of N-(9-(6-aminohexyl)-9-azabicyclo [3.3.1]

nonan-3α-yl)-N'-(methoxy-5-methylphenyl) carbamate [7]

* Indicates included in Pharmacophore Derivation. t Indicates included in CoMFA test set.
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3.2 Materials and Methods

The initial conformer searches and pharmacophore derivation was performed by
DISCOtech using SYBYL 7.2 [23]. The program GALAHAD [24] found within SYBYL
7.2 was unsuccessful in developing a pharmacophore. All CoMFA models were derived
using SYBYL 7.2 [23]. Activity of compounds is based on the rate of dissociation
between the inhibitor and 02 receptor (Ki). Active compounds from each group were
selected for a CoMFA study using Gaussian 98 [26] for geometry optimization. Atomic
charges were calculated using AM1, HF/3-21G*, and B3LYP/3-21G* calculations. These
limits assist in the future development for other 02 ligands.

3.2.1 Pharmacophore Derivation

3.2.1.1 Selection of Ligands. For the derivation of the pharmacophore, eight
moderately to highly active compounds were used: three rigid and five flexible. The three
rigid ligands were selected for setting limitations on the pharmacophore and are listed in
Tables 3.2: Trishomocubane analogue 29 [18, 27], CB-184 28 [26], and BIMU-I 5 [7,
19]. Since 02 sites have much more restrictive structural requirements for high affinity
binding, [28] consideration of the stereochemistry, rigidity, and alkyl chain length are
essential when selecting compounds for the development of a pharmacophore model.
Furthermore, consideration of structural diversity and understanding of biological
activities are necessary [29 - 34].
Non rigid ligands listed in Tables 3.2 - 3.5 were selected based on their 02 affinity
values: N-(9-(6-aminohexyl)-9-azabicyclo [3 .3.1] nonan-3α-yl)-N' -(methoxy -5-
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methylphenyl) carbamate 31 [7], 1-aralkyl-4-benzylpiperidine 17 and 19 [9], 1-aralkyl-4benzylpiperazine 21 [9], and 1-cyclohexylpiperazines 2 [10]. All values were obtained
using [ 3 H] DTG in the presence of 1 1,1M (+)-pentazocine. [ 3 H] (+) pentazocine was used
as the radiolabel for al sites [7, 9, 10, 25]. Histogram pictures of training and test sets are
shown in Figure 3.1. The range of binding affinities for the training set was -2.64 to 0.469
log units, and -1.292 to 0.16 log units for the test set.

(a)

(b)

Figure 3.1 Histogram of pKi (abscissa) vs. number of molecules (ordinate).
(a) Training set, (b) Test set.

3.2.1.2 Choice of Initial Conformations. Conformations of the ligands were
generated using DISCOtech which aligned them by the selection of similar functional
groups within each compound. Two hydrophobic centers were selected, one nitrogen and
one acceptor site. Initial structures were built in SYBYL 7.2 using default bond distances
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and angles. These structures were then minimized using MAX[MIN2 within Tripos
which uses a distance-dependent dielectric function.
DISCOtech recognizes each molecule by ligand points and site points. Ligand
point consisted of a nitrogen center, lone pair of electrons, and two hydrophobic centers
for each compound. Conformational flexibility is handled by computing a series of low
energy conformations for each molecule with each conformer being treated as a rigid
body during the alignment step. The molecule with the fewest conformations is used as a
reference. DISCOtech takes each conformation of the reference molecule in turn and
compares it to all conformations of the other molecules [17, 22]. The resulting
pharmacophore is a four point system with two hydrophobic regions, a nitrogen center
that is approximately 2.90+/- 2.50

A (Figure 3.2).
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Figure 3.2 DISCOtech Pharmacophore Dimensions with hydrophobic (H1 and H2)
regions, nitrogen (N), and Lone Pair (LP) (a and b). Contains 02 receptor ligands 2 (c)
and 28 (d).
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3.2.2 CoMFA Studies

3.2.2.1 Geometry Optimization and Electrostatic Studies. Conformers derived
by DISCOtech were optimized using ab initio HF/3-21G*, B3LYP/3-21G [17] or with
semi-empirical AM1 calculations for 32 compounds (Tables 3.2- 3.7). Electrostatic
charges for these geometries were derived by semi-empirical AM1, ab initio HF/3-21G*
and density functional B3LYP/3-21G according to Mulliken population using Gaussian
98.

3.2.2.2 Alignment. Alignment of presumed bound conformations of the training set
compounds was an essential prelude to the Comparative Molecular Field Analysis
(CoMFA) study [30-35]. The three optimization calculations were aligned by a fit
function in SYBYL 7.2 using a template compound 28 in Table 3.2 and the generated
pharmacophore. Each of the 32 molecules were aligned according to class and overall
geometry using AM1, HF/3-21G*, and B3LYP/3-21G* methods using the ALIGN
DATABASE and "Field Fit" functions [27]. Geometry optimization performed by
Gaussian 98 ensured a reliable CoMFA using Partial Square Least (PLS) validation q 2
and r2 . Ki values were converted to pKi values (pKi = -log [Ki]) [1, 30]. Using a Ki
value, a ligand can be classified based on its selectivity between the two subtypes: al and
a2 [16, 30-35]. Alignments used in the CoMFA model are found in Figure 3.3.
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(a)

(b)

(c)
Figure 3.3 Alignments of all 32 molecules optimized using: AM1 (a), HF/3-21G* (b) and
B3LYP/3-21G* (c) methods.
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3.2.2.3 CoMFA Model. CoMFA columns were generated using the Tripos Standard
CoMFA field class. CoMFA dielectric function of 1/r; a dielectric constant E of 1 extends
every molecule 4.0 A in all directions. A default of 30 kcal/mol energy cutoff for steric
and electrostatic fields was used. The CoMFA standard scaling was used. The CoMFA
column with literature pKi values generated PLS cross validation and validated results
used to predict the bioactivity of ligands (Figure 3.5) [32, 33]. A test set of five molecules
were used to predict pKi values for each of the three calculations (Table 3.9). The training
set values for the three calculations are found in Table 3.10.
PLS analysis diminishes target property against predictors, calculating steric and
electrostatic components of the intermolecular interaction field. The SAMPLS (SAMpledistance PLS) algorithm developed by Bruce Bush [30] was used to determine "
leave-one-out" cross-validation q 2 value. The method for cross-validation was used to 1) to find
if the CoMFA model was productively useful and 2) to decide how many components to
use for the best model. The number of optimal components was considered by the 5%
rule; if the q 2 increases by at least 5% upon increasing the number of components by one,
it is justified to add an additional component. A high q 2 calculated with the training set
only shows a good internal validation, not an automatic high predictive ability for an
external test set [31]. Therefore, the PLS analysis was repeated without cross-validation
using the optimum number of three components. This final analysis yielded a predictive
model, and a CoMFA coefficient contour plot for the steric and electrostatic potential
contributions. The CoMFA model displayed the spatial distribution of important steric
and electrostatic properties affecting the ligands (Figure 3.4).
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Figure 3.4 Graph of experimental (pKi =-log [Ki]) vs. predicted bioactivity by the
CoMFA model using different calculation methods AM1 (a) HF/3-21G* (b) and B3LYP/
3-21G* (c).
*Blue indicates training set while pink indicates test set.
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(a)

(b)

(c)
Figure 3.5 CoMFA contour maps for Compound 2, derived by 62 receptor ligands using
various charge and geometry optimization methods.
*Geometry optimizations and atomic charges were calculated in AM1 (a), HF/3-21G* (b) and B3LYP/
3-21G* (c) methods.
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3.3 Results and Discussions

3.3.1 Pharmacophore
If a ligand has a very low Ki for the target enzyme, then the enzyme ligand complex
formation with the target enzyme will be favored and the selective affinity will be
enhanced. Nahas [36] was able to determine, when looking at N-(3-phenylpropyl)-N'benzylpiperazines, that hydrophobic groups are necessary for the 02 ligands. The
pharmacophore designed by DISCOtech is a four point arrangement and includes the:
nitrogen, lone pair of electrons approximately 2.90

A

from the nitrogen, and two

hydrophobic regions approximately 6.31 A apart (Figure 3.2 a). Figure 3.2b and 3.2c
present Compounds 2 (b) and 28 (c) with the pharmacophore dimensions.

3.3.2 Comparative Molecular Field Analysis
A structural diversity and homogenous range of affinities is necessary to obtain a
significant 3D-QSAR study using the CoMFA method. The CoMFA model required 1 or
3 optimal components in different calculations to explain the variance in binding affinity
to G2 receptor in Table 3.7. The highest q 2 (0.567) was obtained for HF/3-21G* optimized
geometries and atomic charge calculations. The CoMFA models of AM1 optimized
geometries produced lower q 2 (0.321) at one component. This suggests that HF/3-21G*
presents a more accurate variance in activity among similar 62 receptor ligands than AM1
optimized geometries and charges. CoMFA model with B3LYP/3-21G* calculated
geometries and electrostatic charges produced a moderate q 2 (0.382) with three
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components values in comparison to BF/3-21G* with a range of (0.510-0.567) in three
components (Table 3.7).
The cross-validation "leave-one-out" confirmed the predictive ability of the
CoMFA model. PLS analysis performed without any validation produced the best R 2 and
standard errors of predicted pKi values. R 2 measures for HF/3-21G* and B3LYP/3-21G*
methods were 0.991 and 0.996 respectively, and standard errors of estimates were 0.073
and 0.048. AM1 gave the lowest r2 value (0.989) and standard error of estimate of 0.081
(Table 3.8). The relationship between calculated and measured pKi values (predicted) for
non-cross validated analysis is located in Table 3.9 and 3.10.
Table 3.7 Optimal Component Number and q 2 by "One-Leave-Out" using SAMPLS [30]
by the Training Set of 27 Molecules

Table 3.8 QSAR Reports by Non-Crossvalidation using SAMPLS [30] by the Training
Set of 27 Molecules

Standard error of estimation. R2 of non-crossvalidation using training set of 27 molecules in Table 3.2 3.5.
Steric and Electrostatic contributions to this CoMFA field.
-
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Table 3.9 Experimental and Predicted Bioactivities (pKi) by the Training Set of 27
Molecules 'Nina Various Calm] Winn Methods

Table 3.10 Experimental and Predicted Binding Affinities (pKi) by Test Set of Five

Molecules using Various Calculation Methods
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3.3.4 Design of New Ligands
Using the spatial distribution of steric and electrostatic properties, the design of new
ligands and prediction of activities is possible from CoMFA calculations (Figure 3.5).
The contour maps of steric fields are shown in yellow and green. Green areas (80%
contribution) are regions where more bulky substitutions are desired, and yellow (20%
contribution) are regions where less bulk is favorable for higher a2 activity. The contour
maps of electrostatic fields are presented in red and blue; red areas (80% contribution) are
regions that favor more negative charge, and blue areas (20% contribution) are regions
that favor more positive charge for higher a2 activity. AM1 failed to predict PB28 in
proper ranges (Table 3.11).
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Table 3.11 Prediction of Bioactivity of New Ligands

Compounds

Lit pK1

R

X

AM1

HF/3-21G*

B31YP/3-21G*

0.469

OCH3

H

0.468

0.493

0.529

33

-

OCH3

No cyclohexane

0.072

0.422

0.241

34

-

OCH3

0.441

0.668

0.490

37

-

OCH3

F
C1

0.730

0.544

0.466

38

-

H

0.258

0.441

0.165

48

-

OCH2CH3
OCCl3

H

0.369

0.217

0.132

49

-

CO(t-butyl)

H

0.505

0.513

0.573

2 (PB28)

Recently, PB28 2 was found to be one of the few highly selective 02 receptor
ligands [5, 14]. Six structures were suggested (Table 3.11), and predicted pKi values were
calculated using AM1, HF/3-21G*, and B3LYP/3-21G. Since the HF/3-21G* model had
the highest q 2 value, the predicted bioactivity of the new ligands is more probable. Two
locations on the CoMFA maps were investigated to determine the activity of potentially
new compounds (Table 3.11). The first region was on the cyclohexane nearest the
piperazine ring, while the second portion was on the benzocyclohexane. Many 02
receptor ligands have focused on alterations for the second region and have had little
success [2-5, 14]. Using the derived validated CoMFA model, the study of various other
substituent groups can be determined efficiently in less amount of time.
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Among these new structures, 33 and 34 show the highest predicted values
according to the HF/3-21G* model (Table 3.11). When comparing compound 33 to
compound 2, the original ligand had a higher predicted pKi value in the three different
calculations. Therefore a2 receptors are more active with the additional substituents on
the cyclohexane ring. In compound 34 (predicted pKi = 0.668), which has a substitution
of a fluorine on the cyclohexane showed the best predicted pKi value using the HF/
3-21G* PLS analysis. 37 increased the size of the halogen with chlorine showing a drop
in the predicted activity (0.544). However, these two compounds are more active than the
original structure through the ideal location for the substituents in the CoMFA map.
Therefore, there is a possibility of future development of a2 receptor ligands by using
small substituents on the cyclohexane to increase the selectivity and affinity.
To determine the pKi of the benzocyclohexane substituents, many of the ligands
mentioned above had been predicted using the CoMFA [2-5, 14]. The model showed a
large area of positive and negative charge and bulky substituents surrounding the second
region. Various substituents at the methoxy (CH3O) location on the aromatic ring were
tested focusing on these characteristics. Substituents with a bulkier groups such as
methoxy (OCH3), ethyloxy (OCH2CH3), methoxy trichloride (OCCl3), and acyl tert-butyl
(C=0 [t-butyl]) provide a higher affinity for the receptor. The addition of the larger group
generates a localization of electrons on the oxygen. This increases the negativity in the
desired area of the molecules. These compounds had an active range from 0.217 to 0.668
(Table 3.11). Therefore, substituents within this size range which have this
electronegative effect, may be active or have a higher partial affinity with the a2 receptor.
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Other compounds that were suggested and tested in the CoMFA model showed a
significant drop in activity (Appendix). These substituents were electron withdrawing or
had smaller substituents. For instance, compound 35 (predicted pKi = -0.140) with the
hydroxyl (OH) and compound 41 (-0.145) with the bromine (Br) (Appendix).

CHAPTER 4
CONCLUSIONS

This study demonstrated the modified pharmacophore of a2 receptor ligands using
DISCOtech with four points (nitrogen, lone pair of electrons, and two centers of
hydrophobic rings). An alignment of 32 compounds using AM1, HF/3-21G*, and
B3LYP/3-21G* optimized geometries and atomic charges were calculated from methods
on Mulliken populations and the predicting ability of the CoMFA model. Within this
study, HF/3-21G* showed the best reliable ability to predict affinities for the CoMFA.
Two possible sights of modification to a highly active compound 2 were located on the
cyclohexane and cyclohexanebenzene. Both locations showed the addition of electron
donating groups may produce ligands to be more active for the 02 receptor.
With the recent development of PB28, this flexible molecule should be considered
in future studies of 02 receptor ligands. Design and development should focus on a rigid
highly active ligand. Another avenue of development should focus on the development of
naphthalene in place of the benzocyclohexane and substituents with electron donating
groups. Finally, a direct comparison between the σ1 and a2 pharmacophore may be an
effective method to determine more 02 selective receptor ligands.
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APPENDIX
NEW POTENTIAL al RECEPTOR LIGANDS
This table presents new potential C2 receptor ligands that were calculated to be less active
than PB28.
Table A.1 Prediction of Bioactivity of New Ligands That Are Not Active

AM1
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B31YP/3-21G*

Compounds

Lit pKi

R

X

2 (PB28)

0.469

OCH3

H

0.468

0.493

0.529

35

-

OH

H
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36
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NO2

H
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NH2

H
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Br

H

0.338
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-0.406

42
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COOH

H

0.504

-0.399
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43
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OCH3

COOH

0.059
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44
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SH

H

0.339
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45
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OCH3

SH

0.319
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0.338
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COH

H

0.128
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0.475
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-

OCH3

COH
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50
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T-butyl
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36

38

14. Gund, T. M. and Shukla, K. J. Math. Chem. 1991, 8, 309-325.
15. Glennon, R.A. Mini. Rev. Med. Chem. 2005, 5, 927-940.
16. Ablordeppey, S. Y; Fischer, J. B.; Law, H.; and Glennon, R. A. Bioorg. Med. Chem.
2002, 10, 2759-2765.
17. Gund, T.M.; Floyd, J.; and Jung, D. J. Mol. Graph. Model. 2004, 22, 221-230.
18. Nguyen, V.H.; Kassiou, M.; Johnston, G. A.R.; and Christie, M.J. Euro. J. Pharm.
1996, 311, 233-240.
19. Bonhaus, D.W.; Loury, D. N.; Jakeman, L.B.; To, Z.; DeSouza, A.; Eglen, R.M.; and
Wong, E.H.F. J. Pharm. and Exp. Therap. 1993, 267 (2), 961-970.
20. Cratteri, P.; Romanelli, M. N.; Cruciani, G.; Bonaccini, C.; and Melani, F. J. Comp.
Aided. Mol. Des. 2004, 18, 361-374.
21. Cottrell, S.J., Gillet, V. J., and Taylor, R. J. Compute Aided. Mol. Des. 2006, 20,
735-749.
22. Colabufo, N. A.; Abate, C.; Contino, M.; Ingelese, C.; Ferorelli, S.; Berardi, F.; and
Perrone, R. Bioorg. Med. Chem. Letters. 2008, 18, 1484-1488.
23. SYBYL 7.3, Tripos Associates, Inc.: St. Louis, MO, 2006.
24.

GALAHAD™ is distributed by Tripos Inc., 1699 S. Hanley Rd., St. Louis MO
63144, USA (http://www.tripos.com )

25. Marriott D.P.; Dougall, I.G.; Meghani, P.; Liu, Y. J.; and Flower, D.R. J. Med. Chem.
1999, 42, 3210-3216.
26. Frisch, M.J.; Trucks, G.W.; Schlegel, H.B.; Scuseria, G.E.; Robb, M.A.; Cheeseman,
J.R.; Zakrzewski, VG.; Montgomery, IA.; Stratmann, Jr. R. E.; Burant, J.C.;
Dapprich, S.; Millam, J.M.; Daniels, A.D.; Kudin, K.N.; Strain, M.C.; Farkas, 0.;
Tomasi, J.; Barone, V.; Cossi, M.; Cammi, R.; Mennucci, B.; Pomelli, C.; Adamo.
C.; Clifford, S.; Ochteski, J.; Petersson, G.A.; Ayala, P.Y.; Cui, Q.; Morokuma, K.;
Salavador, P.; Dannenberg, J.J.; Malick, D.K.; Rabuck, A.D.; Raghavachari, K.;
Foresman, J.B.; Cioslowski, J.; Ortiz, J.V.; Baboul, A.G.; Stefanov, B.B.; Liu,G.;
Liashenko, A.; Piskorz, P.; Komaromi, I.; Gomperts, R.; Martin, R.L.; Fox, D.J.;
Keith, T.; Al-Laham, M.A.; Peng, C.Y.; Nanayakkara, A.; Challacombe, M.; Gill,
P.M. W.; Johnson, B.; Chen, W.; Wong, M.W.; Andres, J.L.; Gonzalez, C.; Head-

